Effect of Intracoronary Delivery of Autologous Bone Marrow Mononuclear Cells 2 to 3 Weeks Following Acute Myocardial Infarction on Left Ventricular Function The LateTIME Randomized Trial

Title
Effect of Intracoronary Delivery of Autologous Bone Marrow Mononuclear Cells 2 to 3 Weeks Following Acute Myocardial Infarction on Left Ventricular Function The LateTIME Randomized Trial
Author(s)
곽민정Jay H. Traverse[Jay H. Traverse]Timothy D. Henry[Timothy D. Henry]Stephen G. Ellis[Stephen G. Ellis]Carl J. Pepine[Carl J. Pepine]James T. Willerson[James T. Willerson]David X. M. Zhao[David X. M. Zhao]John R. Forder[John R. Forder]Barry J. Byrne[Barry J. Byrne]Antonis K. Hatzopoulos[Antonis K. Hatzopoulos]
Keywords
ENDOTHELIAL PROGENITOR CELLS; MESENCHYMAL STEM-CELLS; RESEARCH NETWORK CCTRN; CARDIAC REPAIR; DOUBLE-BLIND; EJECTION FRACTION; PILOT TRIAL; THERAPY; INFUSION; DETERMINANTS
Issue Date
201111
Publisher
AMER MEDICAL ASSOC
Citation
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, v.306, no.19, pp.2110 - 2119
Abstract
Context Clinical trial results suggest that intracoronary delivery of autologous bone marrow mononuclear cells (BMCs) may improve left ventricular (LV) function when administered within the first week following myocardial infarction (MI). However, because a substantial number of patients may not present for early cell delivery, the efficacy of autologous BMC delivery 2 to 3 weeks post-MI warrants investigation. Objective To determine if intracoronary delivery of autologous BMCs improves global and regional LV function when delivered 2 to 3 weeks following first MI. Design, Setting, and Patients A randomized, double-blind, placebo-controlled trial (LateTIME) of the National Heart, Lung, and Blood Institute-sponsored Cardiovascular Cell Therapy Research Network of 87 patients with significant LV dysfunction (LV ejection fraction [LVEF] <= 45%) following successful primary percutaneous coronary intervention (PCI) between July 8, 2008, and February 28, 2011. Interventions Intracoronary infusion of 150 x 10(6) autologous BMCs (total nucleated cells) or placebo (BMC: placebo, 2:1) was performed within 12 hours of bone marrow aspiration after local automated cell processing. Main Outcome Measures Changes in global (LVEF) and regional (wall motion) LV function in the infarct and border zone between baseline and 6 months, measured by cardiac magnetic resonance imaging. Secondary end points included changes in LV volumes and infarct size. Results A total of 87 patients were randomized (mean [SD] age, 57 [11] years; 83% men). Harvesting, processing, and intracoronary delivery of BMCs in this setting was feasible. Change between baseline and 6 months in the BMC group vs placebo for mean LVEF (48.7% to 49.2% vs 45.3% to 48.8%; between-group mean difference, -3.00; 95% CI, -7.05 to 0.95), wall motion in the infarct zone (6.2 to 6.5 mm vs 4.9 to 5.9 mm; between-group mean difference, -0.70; 95% CI, -2.78 to 1.34), and wall motion in the border zone (16.0 to 16.6 mm vs 16.1 to 19.3 mm; between-group mean difference, -2.60; 95% CI, -6.03 to 0.77) were not statistically significant. No significant change in LV volumes and infarct volumes was observed; both groups decreased by a similar amount at 6 months vs baseline. Conclusion Among patients with MI and LV dysfunction following reperfusion with PCI, intracoronary infusion of autologous BMCs vs intracoronary placebo infusion, 2 to 3 weeks after PCI, did not improve global or regional function at 6 months.
URI
http://hdl.handle.net/YU.REPOSITORY/24315http://dx.doi.org/10.1001/jama.2011.1670
ISSN
0098-7484
Appears in Collections:
이과대학 > 통계학과 > Articles
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE